Navigation Links
Emergence of Cancer Vaccines Will Be the Key Factor Driving the Pancreatic Cancer Drug Market to More Than Double by 2016
Date:9/26/2007

Huge Opportunity Exists for Development of More Effective Therapies That Can Improve Survival, According to a New Report from Decision Resources

WALTHAM, Mass., Sept. 26 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the emergence of cancer vaccines, including drugs from Pharmexa and Cell Genesys, will be the key factor driving the pancreatic cancer drug market to more than double by 2016.

The new Pharmacor report entitled Pancreatic Cancer finds that Pharmexa's GV1001 and Cell Genesys's GVAX will drive the market from $560 million in 2006 to $1.2 billion in 2016 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan. The report also finds that, owing to generic erosion, sales of cytotoxic therapies used in pancreatic cancer -- Eli Lilly's Gemzar, Sanofi-Aventis's Eloxatin/Yakult Honsha's Elplat, Pfizer/Yakult's Campto/Camptosar, Daiichi-Sankyo's Topotecin, and Sanofi-Aventis's Taxotere -- will decline significantly during the next decade.

Although it accounts for only about two percent of all cancers, pancreatic cancer -- one of the most difficult cancers to treat -- is the fourth leading cause of cancer deaths in the United States. As a result, the pancreatic cancer market carries extensive unmet medical need, creating a huge opportunity for the development of more effective therapies that can improve survival.

"In combination with Gemzar, the most promising emerging therapies have failed to improve survival in large-scale, Phase III studies," said Mary Argent-Katwala, Ph.D., director at Decision Resources. "Experts argue that the development model for pancreatic therapies needs to be reviewed, that more effort should be directed at identifying responder subsets at an earlier stage of the disease, and that randomized Phase II studies to identify the most promising drug candidates should be more widely implemented."

About Decision Resources

Decision Resources (http://www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Emergence of Internet video is changing the regulatory landscape
2. Tissue Specificity for Mutation Parallels Tissue Specificity for Cancer
3. Cancer siRNA Oligo Set Version 1.0
4. Cancer-Related miRNAs Uncovered by the mirVana miRNA Microarray Platform
5. Detection of Mutant K-ras in a Kindred With Hereditary Pancreatic Cancer by DGGE
6. Detection of p53 Gene in Breast Cancer by Denaturing Gradient Gel Electrophoresis and the DCode System
7. Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C
8. Genome Wide Profiling of Paired Cancerous and Normal Breast Tissues and Rapid Interpretation of Gene Expression Data
9. NeoClone gets $750K for ovarian cancer detection
10. Quintessence Biosciences advances cancer drug
11. Medical College receives $1.4M cancer grant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... 26, 2016 , ... After several promising treatments in Panama ... City of Knowledge in Panama, a 6 year-old Duchenne’s muscular dystrophy patient received ... year following FDA approval of a second application for a single patient, investigational ...
(Date:5/25/2016)... Portland, Oregon (PRWEB) , ... May 25, 2016 ... ... Base Set features a variety of fracture-specific plating options designed to address fractures ... provide industry-leading fracture fixation solutions. , The Acumed Ankle Plating System 3 is ...
(Date:5/25/2016)... ... May 25, 2016 , ... Lady had been battling arthritis since ... ligament in her left knee. Lady’s owner Hannah sought the help of Dr Jeff ... surgeon, to repair her cruciate ligament and help with the pain of Lady’s arthritis. ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... identity. The new Media Cybernetics corporate branding reflects a results-driven revitalization for a ... image analysis. The re-branding components include a crisp, refreshed logo and a new ...
Breaking Biology Technology:
(Date:4/26/2016)... , April 27, 2016 ... the  "Global Multi-modal Biometrics Market 2016-2020"  report to ... ) , The analysts forecast the ... CAGR of 15.49% during the period 2016-2020.  ... number of sectors such as the healthcare, BFSI, ...
(Date:4/14/2016)... 14, 2016 BioCatch ™, ... today announced the appointment of Eyal Goldwerger ... Goldwerger,s leadership appointment comes at a time ... the deployment of its platform at several of the ... which discerns unique cognitive and physiological factors, is a ...
(Date:3/29/2016)... 29, 2016 LegacyXChange, Inc. (OTC: ... and SelectaDNA/CSI Protect are pleased to announce our successful ... a variety of writing instruments, ensuring athletes signatures against ... collectibles from athletes on LegacyXChange will be assured of ... DNA. Bill Bollander , CEO states, ...
Breaking Biology News(10 mins):